Navigation Links
Experts call for increased neonatal inclusion in pediatric drug trials
Date:10/25/2012

Cincinnati, OH, October 25, 2012 -- Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.

Henry Akinibi, MD, and colleagues from Cincinnati Children's Hospital Medical Center and the University of Cincinnati believe that the lack of clinical drug trials for neonates is caused by many factors, including additional regulatory requirements, no adult equivalents of many neonatal diseases to gain a starting point, lack of financial incentives for pharmaceutical companies, and the unique physiology of neonates. As a result, many doctors prescribe adult-approved drugs for children in off-label and unapproved uses; unfortunately, without clinical trials, the safety of this practice often is unknown and could place neonates at risk for unknown complications.

Throughout the years, the federal government has created legislation in an attempt to gather more information on the medications prescribed for children; the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act were made permanent by Congress in August 2012. These types of legislation have led to over 400 pediatric drug-labeling changes since 1998. Because neonates were addressed in only 6% of these changes, they continue to be at risk for receiving ineffective medications, incorrect dosages, and developing unanticipated complications. Although these new laws now include a requirement that pharmaceutical manufacturers submit plans for pediatric studies at certain times in the drug-approval process (e.g., Phase 2), they do not require a neonatal inclusion. This is important because drawing conclusions from the results of drug trials in older children and applying them to neonates is not ideal and continues to leave this population at risk.

Indisputably, unstudied medications for neonates have played a major role in the positive outcomes and increased viability for infants born prematurely, and, overall, recent laws have resulted in great strides in pediatric trials. However, the neonatal population still lags in inclusion. Of over 120,000 studies at the National Institutes of Health clinical trials repository, only 0.6% involves neonates; in total, only 3.4% of all registered pediatric studies involve neonates. Open communication and cooperative sharing between industry and academics are integral components to ensuring that drugs are safe and effective for all populations. According to the first author of the article, Jason R. Wiles MD, "Inclusion of neonatologists and neonatal pharmacologists in study designs, and early in the drug development process, would make data generated from such studies more relevant and useful."


'/>"/>
Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Experts convene to address major cause of childhood illness and death
2. 4,000 analytics experts come to Phoenix for INFORMS Annual Meeting
3. Swallowed Toothpicks Can Lead to Big Trouble, Experts Warn
4. Lights off? International experts call attention to dangers of exposure to light at night
5. Put Traffic Safety on Back-to-School To-Do List: Experts
6. Experts Offer Tips to Help Keep Fall Sports Injury Free
7. Experts recommend screening adults for hypertriglyceridemia every five years
8. Alzheimers experts from Penn Summit provide strategic roadmap to tackle the disease
9. Experts warn that e-cigarettes can damage the lungs
10. Snoring Kids Should Be Screened for Sleep Apnea: Experts
11. Add Hurricane Menu to Your Storm Prep, Experts Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All ... is the creation of published author, Keith C. A. Tucker, son of Minister Delores ... World Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, I ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, ... Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The Aerolib ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network announced the ... 503A compounding pharmacy located in Ocala, Florida. , Meeting the Needs of ... the United States for high-quality human anti-aging and wellness compounded medications, ...
(Date:1/19/2017)... Beach, Florida (PRWEB) , ... January 19, 2017 , ... ... J.D., LCSW, announced that the name of their drug rehab center in Delray Beach, ... time we recognize that not only stars such as Philip Seymour Hoffman and Chris ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD 12.3 billion ... heightening prevalence of cardiac conditions coupled with the availability of medical coverage is ... enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY ), makers ... radiation therapy system, announced today that it has raised ... a private placement of its common stock and ... was joined by certain of ViewRay,s existing investors, ... and an additional new institutional investor, Acuta Capital ...
(Date:1/19/2017)...  Magnetic Insight Inc., leader in magnetic particle ... with inviCRO LLC to develop intuitive image analysis ... on inviCRO,s VivoQuant™ visualization and post processing software ... MPI solution package with the Momentum MPI imaging ... in vivo. MPI is a groundbreaking ...
Breaking Medicine Technology: